{"entity":{"id":"nct07121946","kind":"trial","name":"This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma","aka":[],"tldr":"A phase 1 trial of LTZ-301 run by LTZ Therapeutics, Inc., now recruiting.","summary":"This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma is a phase 1 interventional study registered as NCT07121946 by LTZ Therapeutics, Inc., with 42 participants planned, started 2026-01-29. Conditions recorded: Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL) and Marginal Zone Lymphoma (MZL). Interventions recorded: LTZ-301, LTZ-301 and LTZ-301.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07121946","url":"https://clinicaltrials.gov/study/NCT07121946"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","dlbcl","follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["ltz-301"],"companies":["ltz-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07121946","phase":"1","setting":"A Phase 1, Open-label, Multicenter Study of LTZ-301 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma","sponsor":"LTZ Therapeutics, Inc.","enrolled":42,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07121946/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"ltz-301","kind":"drug","name":"LTZ-301","route":"/drugs/ltz-301/"}],"company":[{"id":"ltz-therapeutics","kind":"company","name":"LTZ Therapeutics","route":"/companies/ltz-therapeutics/"}]}}